<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04056949</url>
  </required_header>
  <id_info>
    <org_study_id>NCC1977</org_study_id>
    <nct_id>NCT04056949</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide Chemotherapy</brief_title>
  <official_title>The Efficacy and Safety of IBI308 Combined With Paclitaxel/Albumin-Bound Paclitaxel as Second-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer That Relapsed After Failing to Platinum-Etoposide Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Junling Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well IBI308 combined with paclitaxel/albumin-bound paclitaxel&#xD;
      work in treating participants with small cell lung cancer after failing to platinum-etoposide&#xD;
      chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective :&#xD;
&#xD;
      To estimate progression free survival (PFS) probability of patient who recurrent SCLC treated&#xD;
      with IBI308 combined with paclitaxel/abumin-bound paclitaxel following progression on&#xD;
      platinum-etoposide chemotherapy.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      I.To evaluate the objective remission rate (ORR), disease control rate. (DCR),durative time&#xD;
      of remission ( DoR）and overall survival (OS) of IBI308 combined with paclitaxel/abumin-bound&#xD;
      paclitaxel following progression on platinum-etoposide chemotherapy.&#xD;
&#xD;
      II.To evaluate the safety of IBI308 combined with paclitaxel/abumin-bound paclitaxel&#xD;
      following progression on platinum-etoposide chemotherapy.&#xD;
&#xD;
      Exploratory Objectives To evaluate the correlation of biomarkers with efficacy and toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 5, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>SCLC patients who have failed platinum-etoposide chemotherapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival (PFS)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease control rate (DCR)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>durative time of remission ( DoR）</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective remission rate (ORR)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Extensive-Stage Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>IBI308 + Paclitaxel/Albumin-Bound Paclitaxel</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>IBI308 Combined with Albumin-Bound Paclitaxe</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel/Albumin-Bound Paclitaxel</intervention_name>
    <description>Paclitaxel 175mg/m2 IV on day 1of 21 days cycle ;Number of Cycles: 4-6; or Albumin-bound paclitaxel 130mg/m2 IV on day 1 and 8 of 21 days cycle ;Number of Cycles: 4-6;</description>
    <arm_group_label>IBI308 + Paclitaxel/Albumin-Bound Paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI308</intervention_name>
    <description>IBI308 200mg IV infusion, every 3 weeks,until disease progress or intolerable toxicity,used up to 1 year (or 16 cycles)</description>
    <arm_group_label>IBI308 + Paclitaxel/Albumin-Bound Paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent;&#xD;
&#xD;
          2. Over 18 years old and below 70 years old;&#xD;
&#xD;
          3. Histologically confirmed small-cell lung cancer;&#xD;
&#xD;
          4. Extensive disease(ED) according to the criteria of the Veteran's Administration Lung&#xD;
             Cancer Group: (disease extended is defined as a disease beyond hemi thorax and&#xD;
             supraclavicular lymph node areas.);&#xD;
&#xD;
          5. ED-SCLC treated with platinum-etoposide chemotherapy ,followed by disease progression&#xD;
             or recurrence.&#xD;
&#xD;
          6. Availability of a biomarker detection tissue biopsy is required;&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) performance status 0~1;&#xD;
&#xD;
          8. Life expectancy of greater than 12 weeks;&#xD;
&#xD;
          9. Participants may have evaluable or measurable disease, defined as at least one&#xD;
             lesion（no previous radiotherapy）that can be accurately measured in at least one&#xD;
             dimension with spiral CT scan, MRI within the past 28 days;&#xD;
&#xD;
         10. Women of child-bearing potential and men must agree to use adequate contraception&#xD;
             prior to initiation of therapy and until to 6 month after this study;&#xD;
&#xD;
         11. White blood cell ≥ 3.5 × 109/L, absolute neutrophil count ≥1.5 × 109/L, platelet ≥100×&#xD;
             109/L and hemoglobin ≥9.0 g/dL;&#xD;
&#xD;
         12. Aspartate transferase,alanine aminotransferase ≤ 2.5 x ULN except in case of liver&#xD;
             metastases (5 x ULN); Total bilirubin ≤1.5 x ULN except in case of Gilbert syndrome&#xD;
             (3.0 mg/dL); Albumin≥3 g/dL;&#xD;
&#xD;
         13. Serum creatinine ≤1.5×ULN OR creatinine clearance≥40 mL/min;&#xD;
&#xD;
         14. Lipase &lt; 1.5 x ULN except in case of having no clinical or imaging evidence of&#xD;
             pancreatitis; Amylase ≤1.5 x ULN except in case of having no clinical or imaging&#xD;
             evidence of pancreatitis; Alkaline phosphatase (ALP) ≤ 2.5 ULN except in case of bone&#xD;
             metastasis;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Mixed lung cancer or other types of lung cancer;&#xD;
&#xD;
          2. Prior immunotherapy, included but not limited to cytotoxic T lymphocyte-associated&#xD;
             antigen-4 (CTLA-4) inhibitors, PD-1 inhibitors, PD-L1/2 inhibitors or other drugs&#xD;
             targeting T cells;&#xD;
&#xD;
          3. Received high-dose radiation therapy in thoracic field within the past 6 months, Dt (&gt;&#xD;
             30 Gy);&#xD;
&#xD;
          4. Active or untreated central nervous system (CNS) metastases;&#xD;
&#xD;
          5. Patients with cytologically positive pleural, peritoneal or pericardial fluid are not&#xD;
             eligible;&#xD;
&#xD;
          6. History of autoimmune disease.Patients with a history of hypothyroidism origin&#xD;
             autoimmune treated with a stable dose replacement therapy may be eligible for this&#xD;
             study. Patients with controlled type 1 diabetes treated with insulin are eligible in&#xD;
             this study;&#xD;
&#xD;
          7. Corticosteroid with a daily dose over 10 mg prednisolone or other immunosuppressive&#xD;
             agents were used within 14 days before the first cycle;&#xD;
&#xD;
          8. Patients should not receive a vaccine during the four weeks preceding the day 1 of&#xD;
             cycle 1, and shall not receive a vaccine during the study;&#xD;
&#xD;
          9. Idiopathic pulmonary fibrosis history, radioactive pneumonia requiring steroid&#xD;
             therapy, organizing pneumonia (eg, bronchiolitis obliterans), drug-induced lung&#xD;
             disease, idiopathic pulmonary or active signs of pneumonia or interstitial lung&#xD;
             infiltrate (any cause) detected on the lung scan selection;&#xD;
&#xD;
         10. History of active Bacillus Tuberculosis;&#xD;
&#xD;
         11. Except hair loss and fatigue, toxicities caused by previous anti-cancer therapies need&#xD;
             to be restored to &lt; CTCAE 4.03 grade 1 before starting treatment on protocol;&#xD;
&#xD;
         12. History of any one or more of the following conditions within the past 6&#xD;
             months:symptomatic peripheral vascular disease, pulmonary embolism or untreated deep&#xD;
             venous thrombosis (DVT), cerebrovascular accident or transient ischemic attack;&#xD;
&#xD;
         13. History of any one or more of the following conditions within the past 6 months:&#xD;
             gastrointestinal ulcer, gastrointestinal perforation, corrosive esophagitis or&#xD;
             gastritis, inflammatory bowel disease or diverticulitis, abdominal fistula,&#xD;
             tracheoesophageal fistula or abdominal abscess;&#xD;
&#xD;
         14. History of any one or more of the following cardiovascular conditions: Class III or IV&#xD;
             congestive heart failure, as defined by the New York Heart Association; Unstable&#xD;
             angina; Myocardial infarction within the past 6 months; Supraventricular or&#xD;
             ventricular arrhythmia requires treatment or intervention;&#xD;
&#xD;
         15. Severe uncontrolled hypertension (systolic blood pressure ≥160 mmHg and/or diastolic&#xD;
             blood pressure ≥ 100mmHg);&#xD;
&#xD;
         16. Tumors compress surrounding vital organs, such as the esophagus, with associated&#xD;
             symptoms;&#xD;
&#xD;
         17. Uncontrolled hypercalcemia;&#xD;
&#xD;
         18. History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to monoclonal antibody;&#xD;
&#xD;
         19. Prior malignancy. Note: Patients who have had another malignancy and were treated more&#xD;
             than 5 years ago and have since been considered cured, or patients with a history of&#xD;
             basocellular skin carcinoma or in situ carcinoma of the uterine cervix are eligible;&#xD;
&#xD;
         20. Mental illness, alcoholism, inability to quit smoking, drug abuse or drug abuse;&#xD;
&#xD;
         21. History of human immunodeficiency virus infection or has known active Hepatitis B&#xD;
             (e.g., HBsAg reactive) or Hepatitis C Virus (HCV) (e.g., HCV RNA is detected).&#xD;
&#xD;
         22. Pregnant or lactating female;&#xD;
&#xD;
         23. Any type of systemic anticancer therapy (chemotherapy or experimental drugs) within 4&#xD;
             weeks of starting treatment on protocol;&#xD;
&#xD;
         24. Other situations judged by researchers;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junling Li, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Junling Li, doctor</last_name>
    <phone>+86 13801178891</phone>
    <email>lijunling@cicams.ac.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Junling Li</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junling Li, Doctor</last_name>
      <phone>+86 13801178891</phone>
      <email>lijunling@cicams.ac.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 9, 2019</study_first_submitted>
  <study_first_submitted_qc>August 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2019</study_first_posted>
  <last_update_submitted>August 13, 2019</last_update_submitted>
  <last_update_submitted_qc>August 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College</investigator_affiliation>
    <investigator_full_name>Junling Li</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>SCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

